Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
alleging, arbitration, asserting, binding, breach, brought, cancellation, conversion, counterparty, documentary, imputed, intense, interpretation, interpreted, largest, lawsuit, letter, light, mentioned, Ontario, PIO, proceeding, progressed, retrospectively, reverse, split, surrendered, theory, thereunder, vigorously
Removed:
accounted, comprehensive, decision, face, individually, listing, realized
Filing tables
Filing exhibits
INM similar filings
Filing view
External links
Exhibit 32.2
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Jonathan Tegge, the Chief Financial Officer of InMed Pharmaceuticals Inc. (the “Company”), hereby certify that, to my knowledge:
1. | The Quarterly Report on Form 10-Q for the quarter ended December 31, 2022 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: February 17, 2023
/s/ Jonathan Tegge | |
Name: Jonathan Tegge | |
Title: Interim Chief Financial Officer |